Intus Biosciences is a brand founded by a team of experts in Next Generation Sequencing (NGS) technology, with a strong focus on harnessing its power for bacteria identification. Understanding the critical role bacteria plays in health, Intus Biosciences has developed the pioneering Intus Bio Titan-1 Platform, which is fueled by their patented and proprietary technology. This platform is considered the most powerful of its kind worldwide.

The company's efforts in this field have been highly successful, with Intus Bio's groundbreaking insights benefiting pharmaceutical and biotherapeutic companies. Additionally, it has led to the development of cutting-edge services for patients. The team at Intus Biosciences is led by CEO Paul Denslow, who brings a wealth of experience in bio-tech investment and a strong belief in utilizing big data to drive better health outcomes.

Together, they are revolutionizing the field of bacteria identification and its impact on healthcare